Global Uveitis Treatment Market

 

Uveitis is the term that describes a group of inflammatory diseases that affect the eye and produces swelling. Uveitis can reduce sight and may cause vision loss. Causes of uveitis include infections such as brucellosis, leptospirosis, syphilis, tuberculosis, autoimmune diseases such as sarcoidosis, Crohn’s disease, multiple sclerosis, arthritis, ankylosing spondylitis, and psoriatic arthritis. In addition, uveitis is also caused by drugs such as rifabutin and moxifloxacin. Uveitis affects uvea, lens, retina, optic nerve, and vitreous. Uveitis can be classified into anterior uveitis, intermediate uveitis, posterior uveitis and pan-uveitis based on part of inflammation.

 

The main driver for the growth of uveitis market is the rise in prevalence and complications related to uveitis. In addition, increase in prevalence rates, market players betting heavily on research and development to develop new drugs, an introduction of biologics into the market, fast approval of the drugs are fueling the market growth of uveitis treatment market. According to the Ocular Immunology and Uveitis Foundation, worldwide 2,359,242 people are estimated to have the disorder. Even there are significant advances in research and therapeutics, a prevalence of blindness secondary to uveitis has not been reduced in the past thirty years. However, few factors are restraining the growth of the market such as side effects of the drugs, eye irritation and lack of awareness about eye disorders in undeveloped regions, lack of sufficient healthcare infrastructure is hindering the uveitis treatment system market.

 

Uveitis treatment market segmented based on drug class, disease type, by cause and distribution channel

 

 

Based on drug class, uveitis drugs market is segmented into

• Corticosteroids
• Immunosuppressant
• Monoclonal antibodies
• Antibiotics
• Antivirals
• Antifungal
• Analgesics

 

Based on disease type, uveitis drugs market is segmented into

• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Panuveitis

 

Based on cause, uveitis drugs market is segmented into

• Infectious Uveitis
• Non-Infectious Uveitis

 

Based on distribution channel, uveitis drugs market is segmented into

• Hospital Pharmacies
• Retail Pharmacies
• Others

 

Market players are developing novel molecules that can treat uveitis conditions in order to enhance their sales revenue. Companies are focusing on the development of the various drugs in the treatment of the uveitis. For instance, Aurinia Pharmaceuticals Inc. developing Luvenia, a calcineurin inhibitor for the treatment of noninfectious uveitis. Recently it has completed its phase-II clinical trials. Similarly, other pipeline drugs such as EMEA, DE-109, Gevokizumab, Peptide B27PD are being developed by different companies. Considering the aforementioned factors global uveitis treatment market is expected to grow at the significant rate during the forecast period.

 

Geographically global uveitis treatment market segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is leading in uveitis treatment market due to various factors such as early approval of drugs compared to other regions, increased R&D investments by market players, and high prevalence of the uveitis is contributing growth of the market. In Europe region due to increased prevalence of diseases such as HIV, multiple sclerosis that are underlying causes of uveitis conditions. Japan, China, and India are expected to play important role in the revenue growth of the Asia-Pacific uveitis treatment market. China and India market growth is due to rapidly developing healthcare infrastructure, increased research and development expenditure and growing awareness about the eye-related diseases. However, manufacturing of eye preparations required aseptic conditions and the manufacturing plant should be GMP certified. Hence the cost related to these preparations is very high that has the direct implication on a cost of the drugs.

 

Some of the players in global uveitis treatment market include AbbVie Inc. (U.S.), Eyegate Pharmaceuticals Inc. (US), Valeant Pharmaceuticals (Bausch + Lomb) (Canada), Novartis AG (Switzerland), Alimera Sciences Inc. (U.S.) and Santen Pharmaceutical Co. Ltd (Japan) to name a few.

 

• In June 2016, U.S. Food and Drug Administration approved AbbVie’s HUMIRA for the treatment of non-infectious intermediate, posterior and panuveitis

 

Report Outline:

 

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Table of Content

1.Executive summary

2. Global Uveitis Treatment Market Introduction

              2.1. Global Uveitis Treatment Market – Taxonomy

              2.2. Global Uveitis Treatment Market –Definitions

                             2.2.1. Drug Class Type

                             2.2.2. Disease Type

                             2.2.3. Cause

                             2.2.4. Distribution Channel

3. Global Uveitis Drugs Market Dynamics

              3.1. Drivers

              3.2. Restraints

              3.3. Opportunities/Unmet Needs of the Market

              3.4. Trends

              3.5. Global Uveitis Treatment Market Dynamics – Factors Impact Analysis

              3.6. Global Uveitis Treatment Market – Regulations

                             3.6.1. U.S

                             3.6.2. Europe

                             3.6.3. Japan

                             3.6.4. China

              3.7. Global Uveitis Treatment Market – Product Innovations

4. Global Uveitis Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

              4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

              4.3. Market Oppurtunity Analysis

5. Global Uveitis Treatment Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024

              5.1. Corticosteroids

                             5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             5.1.3. Market Opportunity Analysis

              5.2. Immunosuppressant

                             5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             5.2.3. Market Opportunity Analysis

              5.3. Monoclonal antibodies

                             5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             5.3.3. Market Opportunity Analysis

              5.4. Antibiotics

                               5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             5.4.3. Market Opportunity Analysis

              5.5. Antivirals

                             5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             5.5.3. Market Opportunity Analysis

              5.6. Antifungal

                             5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             5.6.3. Market Opportunity Analysis

              5.7. Analgesics

 

                             5.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             5.7.3. Market Opportunity Analysis

6. Global Uveitis Treatment Market Forecast, By Disease Type, 2013 – 2017 and Forecast, 2018 – 2024

              6.1. Anterior Uveitis

                             6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             6.1.3. Market Opportunity Analysis

              6.2. Posterior Uveitis

                             6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             6.2.3. Market Opportunity Analysis

              6.3. Intermediate Uveitis

                             6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             6.3.3. Market Opportunity Analysis

              6.4. Panuveitis

                             6.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             6.4.3. Market Opportunity Analysis

7. Global Uveitis Drugs Market Forecast, By Cause, 2013 – 2017 and Forecast, 2018 – 2024

              7.1. Infectious Uveitis

                             7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             7.1.3. Market Opportunity Analysis

              7.2. Non-Infectious Uveitis

                             7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             7.2.3. Market Opportunity Analysis

8. Global Uveitis Treatment Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024

              8.1. Hospital Pharmacies

                             8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             8.1.3. Market Opportunity Analysis

              8.2. Retail Pharmacies

                             8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)              

                             8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             8.2.3. Market Opportunity Analysi

              8.3. Others

                             8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             8.3.3. Market Opportunity Analysis

9. Global Uveitis Treatment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024

              9.1. North America

                             9.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             9.1.3. Market Opportunity Analysis

              9.2. Europe

                             9.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             9.2.3. Market Opportunity Analysis

              9.3. Asia-Pacific

                             9.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             9.3.3. Market Opportunity Analysis

              9.4. Latin America

                             9.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             9.4.3. Market Opportunity Analysis

              9.5. Middle East and Africa

                             9.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                             9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                             9.5.3. Market Opportunity Analysis

            9.6. Global Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class Type, By  Disease Type, Cause, Distribution Channel, and Region, 2018 – 2024

10. North America Uveitis Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

                             10.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                                                  10.1.1.1. Corticosteroids

                                                  10.1.1.2. Immunosuppressant

                                                  10.1.1.3. Monoclonal antibodies

                                                  10.1.1.4. Antibiotics

                                                  10.1.1.5. Antivirals

                                                  10.1.1.6. Antifungal

                                                  10.1.1.7. Analgesics

                             10.1.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  10.1.2.1. Anterior Uveitis

                                                  10.1.2.2. Posterior Uveitis

                                                  10.1.2.3. Intermediate Uveitis

                                                  10.1.2.4. Panuveitis

                                                  10.1.3. Cause Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  10.1.3.1. Infectious Uveitis

                                                  10.1.3.2. Non Infectious Uveitis

                             10.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  10.1.4.1. Hospital Pharmacies

                                                  10.1.4.2. Retail Pharmacies

                                                  10.1.4.3. Others

                                                  10.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

                                                  10.1.5.1. U.S.

                                                  10.1.5.2. Canada

                             10.1.6. North America Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2018 – 2024

                                                  10.1.7. North America Uveitis Treatment Market Dynamics – Trends

11. Europe Uveitis Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

                             11.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                                                  11.1.1.1. Corticosteroids

                                                  11.1.1.2. Immunosuppressant

                                                  11.1.1.3. Monoclonal antibodies

                                                  11.1.1.4. Antibiotics

                                                  11.1.1.5. Antivirals

                                                  11.1.1.6. Antifungal

                                                  11.1.1.7. Analgesics

                             11.1.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  11.1.2.1. Anterior Uveitis

                                                  11.1.2.2. Posterior Uveitis

                                                  11.1.2.3. Intermediate Uveitis

                                                  11.1.2.4. Panuveitis

                             11.1.3. Cause Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  11.1.3.1. Infectious Uveitis

                                                  11.1.3.2. Non Infectious Uveitis

                                                  11.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  11.1.4.1. Hospital Pharmacies

                                                  11.1.4.2. Retail Pharmacies

                                                  11.1.4.3. Others

                             11.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  11.1.5.1. Germany

                                                  11.1.5.2. UK

                                                  11.1.5.3. France

                                                  11.1.5.4. Spain

                                                  11.1.5.5. Italy

                                                  11.1.5.6. Russia

                                                  11.1.5.7. Poland

                                                  11.1.5.8. Rest of Europe

                                                  11.1.6. Europe Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2018 – 2024

                             11.1.7. Europe Uveitis Treatment Market Dynamics – Trends

12. Asia-Pacific Uveitis Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

                             12.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                                                  12.1.1.1. Corticosteroids

                                                  12.1.1.2. Immunosuppressant

                                                  12.1.1.3. Monoclonal antibodies

                                                  12.1.1.4. Antibiotics

                                                  12.1.1.5. Antivirals

                                                  12.1.1.6. Antifungal

                                                  12.1.1.7. Analgesics

                             12.1.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  12.1.2.1. Anterior Uveitis

                                                  12.1.2.2. Posterior Uveitis

                                                  12.1.2.3. Intermediate Uveitis

                                                  12.1.2.4. Panuveitis

                             12.1.3. Cause Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  12.1.3.1. Infectious Uveitis

                                                  12.1.3.2. Non Infectious Uveitis

                             12.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  12.1.4.1. Hospital Pharmacies

                                                  12.1.4.2. Retail Pharmacies

                                                  12.1.4.3. Others

                             12.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

                                                  12.1.5.1. Japan

                                                  12.1.5.2. China

                                                  12.1.5.3. India

                                                  12.1.5.4. ASEAN

                                                  12.1.5.5. Australia & New Zealand

                                                  12.1.5.6. Rest of Asia-Pacific

                             12.1.6. Asia-Pacific Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2018 – 2024

                             12.1.7. Europe Uveitis Treatment Market Dynamics – Trends

13. Latin America Uveitis Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

                             13.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                                                  13.1.1.1. Corticosteroids

                                                  13.1.1.2. Immunosuppressant

                                                  13.1.1.3. Monoclonal antibodies

                                                  13.1.1.4. Antibiotics

                                                  13.1.1.5. Antivirals

                                                  13.1.1.6. Antifungal

                                                  13.1.1.7. Analgesics

                             13.1.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  13.1.2.1. Anterior Uveitis

                                                  13.1.2.2. Posterior Uveitis

                                                  13.1.2.3. Intermediate Uveitis

                                                  13.1.2.4. Panuveitis

                             13.1.3. Cause Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  13.1.3.1. Infectious Uveitis

                                                  13.1.3.2. Non Infectious Uveitis

                             13.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  13.1.4.1. Hospital Pharmacies

                                                  13.1.4.2. Retail Pharmacies

                                                  13.1.4.3. Others

                             13.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  13.1.5.1. Brazil

                                                  13.1.5.2. Mexico

                                                  13.1.5.3. Argentina

                                                  13.1.5.4. Venezuela

                                                  13.1.5.5. Rest of Latin America

                             13.1.6. Latin America Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2018 – 2024

                             13.1.7. Latin America Uveitis Treatment Market Dynamics – Trends

14. Middle East and Africa Uveitis Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

                             14.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                                                  14.1.1.1. Corticosteroids

                                                  14.1.1.2. Immunosuppressant

                                                  14.1.1.3. Monoclonal antibodies

                                                  14.1.1.4. Antibiotics

                                                  14.1.1.5. Antivirals

                                                  14.1.1.6. Antifungal

                                                  14.1.1.7. Analgesics

                             14.1.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  14.1.2.1. Anterior Uveitis

                                                  14.1.2.2. Posterior Uveitis

                                                  14.1.2.3. Intermediate Uveitis

                                                  14.1.2.4. Panuveitis

                             14.1.3. Cause Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  14.1.3.1. Infectious Uveitis

                                                  14.1.3.2. Non Infectious Uveitis

                             14.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                  14.1.4.1. Hospital Pharmacies

                                                  14.1.4.2. Retail Pharmacies

                                                  14.1.4.3. Others

                             14.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                                                  14.1.5.1. Gulf Cooperation Council (GCC) Countries

                                                  14.1.5.2. Israel

                                                  14.1.5.3. South Africa

                                                  14.1.5.4. Rest of MEA

                                                  14.1.6. MEA Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2018 – 2024

                                                  14.1.7. MEA Uveitis Treatment Market Dynamics – Trends

15. Competition Landscape

              15.1. Strategic Dashboard of Top Market Players

              15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

                                                  15.2.1. AbbVie Inc. (U.S.)

                                                  15.2.2. Eyegate Pharmaceuticals Inc. (U.S.)

                                                  15.2.3. Valeant Pharmaceuticals (Bausch + Lomb) (Canada)

                                                  15.2.4. Novartis AG (Switzerland)

                                                  15.2.5. Alimera Sciences Inc. (U.S.)

                                                  15.2.6. Santen Pharmaceutical Co. Ltd (Japan)

 

16. Research Methodology
17. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

ASK ANALYST

OR

 

Request Customisation